B cells and their mediators as targets for therapy in solid tumors

Andrew J. Gunderson, Lisa Coussens

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

B cells have recently been appreciated as paracrine mediators of solid tumor development. Their ability to influence various hallmarks of cancer development, aside from antigen presentation, can be attributed to the diversity of soluble mediators they express, including cytokines and immunoglobulins, that can act directly and indirectly on the diversity of leukocyte subsets that infiltrate developing tumors, evolving neoplastic cells, as well as select T cell populations in secondary lymphoid organs and within tumor stroma. Herein, we review the literature supporting these interactions and discuss novel approaches to ameliorate protumoral B cell effects for anti-cancer therapy.

Original languageEnglish (US)
Pages (from-to)1644-1649
Number of pages6
JournalExperimental Cell Research
Volume319
Issue number11
DOIs
StatePublished - Jul 1 2013

Fingerprint

B-Lymphocytes
Neoplasms
Therapeutics
Antigen Presentation
Immunoglobulins
Leukocytes
Cytokines
T-Lymphocytes
Population

Keywords

  • B cells
  • Cancer
  • Inflammation
  • Leukocytes
  • Myeloid cells

ASJC Scopus subject areas

  • Cell Biology

Cite this

B cells and their mediators as targets for therapy in solid tumors. / Gunderson, Andrew J.; Coussens, Lisa.

In: Experimental Cell Research, Vol. 319, No. 11, 01.07.2013, p. 1644-1649.

Research output: Contribution to journalArticle

@article{98d26374a07041e2a80e47278bb9dab3,
title = "B cells and their mediators as targets for therapy in solid tumors",
abstract = "B cells have recently been appreciated as paracrine mediators of solid tumor development. Their ability to influence various hallmarks of cancer development, aside from antigen presentation, can be attributed to the diversity of soluble mediators they express, including cytokines and immunoglobulins, that can act directly and indirectly on the diversity of leukocyte subsets that infiltrate developing tumors, evolving neoplastic cells, as well as select T cell populations in secondary lymphoid organs and within tumor stroma. Herein, we review the literature supporting these interactions and discuss novel approaches to ameliorate protumoral B cell effects for anti-cancer therapy.",
keywords = "B cells, Cancer, Inflammation, Leukocytes, Myeloid cells",
author = "Gunderson, {Andrew J.} and Lisa Coussens",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.yexcr.2013.03.005",
language = "English (US)",
volume = "319",
pages = "1644--1649",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "11",

}

TY - JOUR

T1 - B cells and their mediators as targets for therapy in solid tumors

AU - Gunderson, Andrew J.

AU - Coussens, Lisa

PY - 2013/7/1

Y1 - 2013/7/1

N2 - B cells have recently been appreciated as paracrine mediators of solid tumor development. Their ability to influence various hallmarks of cancer development, aside from antigen presentation, can be attributed to the diversity of soluble mediators they express, including cytokines and immunoglobulins, that can act directly and indirectly on the diversity of leukocyte subsets that infiltrate developing tumors, evolving neoplastic cells, as well as select T cell populations in secondary lymphoid organs and within tumor stroma. Herein, we review the literature supporting these interactions and discuss novel approaches to ameliorate protumoral B cell effects for anti-cancer therapy.

AB - B cells have recently been appreciated as paracrine mediators of solid tumor development. Their ability to influence various hallmarks of cancer development, aside from antigen presentation, can be attributed to the diversity of soluble mediators they express, including cytokines and immunoglobulins, that can act directly and indirectly on the diversity of leukocyte subsets that infiltrate developing tumors, evolving neoplastic cells, as well as select T cell populations in secondary lymphoid organs and within tumor stroma. Herein, we review the literature supporting these interactions and discuss novel approaches to ameliorate protumoral B cell effects for anti-cancer therapy.

KW - B cells

KW - Cancer

KW - Inflammation

KW - Leukocytes

KW - Myeloid cells

UR - http://www.scopus.com/inward/record.url?scp=84879604267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879604267&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2013.03.005

DO - 10.1016/j.yexcr.2013.03.005

M3 - Article

C2 - 23499742

AN - SCOPUS:84879604267

VL - 319

SP - 1644

EP - 1649

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 11

ER -